middle.news
FDA Endorses Neurizon’s Strategy to Lift Clinical Hold on NUZ-001
9:24am on Thursday 10th of July, 2025 AEST
•
Biotechnology
Read Story
FDA Endorses Neurizon’s Strategy to Lift Clinical Hold on NUZ-001
9:24am on Thursday 10th of July, 2025 AEST
Key Points
FDA provides written confirmation supporting Neurizon’s clinical hold resolution strategy
Two preclinical pharmacokinetic studies completed ahead of schedule
Complete Response submission to FDA expected in coming weeks
Targeting participation in HEALEY ALS Platform Trial in Q4 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE